GlassScriptPhysician profile
Emilio Mazza
NPI 1184663239
$6,852.14
in general payments reported to CMS, 2019-2025
37 companies · $2,490 in 2025
The $2,490 reported for 2025 was more than what 89% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $285 · 2021: $131 · 2022: $395 · 2023: $1,434 · 2024: $1,802 · 2025: $2,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,578 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,578.16 |
| Education | $147.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,941.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,801.18 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $419.36 | 2019-2025 | |
| Harmony Biosciences LLC | $361.07 | 2020-2025 | Wakix |
| Philips North America LLC | $245.21 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $184.74 | 2023-2025 | Dupixent |
| Verona Pharma, INC. | $160.24 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $148.11 | 2020-2025 | Aralast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.82 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Vapotherm INC | $131.51 | 2019-2021 | |
| United Therapeutics Corporation | $130.03 | 2023-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $127.62 | 2023-2025 | Tezspire |
| Inspire Medical Systems, INC. | $115.11 | 2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $89.72 | 2024-2025 | Lumryz |
| Ceribell, INC. | $85.13 | 2024 | Pocket Eeg Device |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Baxter Healthcare | $72.57 | 2023 | Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $59.65 | 2019-2025 | |
| Axsome Therapeutics, INC. | $53.84 | 2023-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $43.75 | 2019-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $43.15 | 2023-2024 | Belsomra, Winrevair |
| Grifols USA, LLC | $42.02 | 2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $36.98 | 2025 | Wegovy |
| Resmed Corp | $35.64 | 2020-2025 | |
| Pfizer INC. | $33.01 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.63 | 2024 | |
| Insmed, INC. | $32.43 | 2024-2025 | Brinsupri, Arikayce |
| Mylan Specialty L.P. | $31.77 | 2023-2024 | Yupelri |
| Electromed, INC. | $31.74 | 2023-2024 | Smartvest |
| Viatris Specialty LLC | $29.94 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $23.48 | 2025 | Purified Cortrophin Gel |
| Lungpacer Medical USA INC | $21.98 | 2025 | Aeropace Neurostimulation Console |
| Vifor Pharma, INC. | $16.99 | 2024 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $15.76 | 2023 | Airduo Digihaler |
| Alexion Pharmaceuticals, INC. | $15.60 | 2024 | Ultomiris |
| Lilly USA, LLC | $14.69 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilio Mazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.